If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research interests

The ability of Mycobacterium tuberculosis (Mtb) to persist in the presence of anti-mycobacterial drugs and immune effector functions is the greatest obstacle in our attempt to eradicate tuberculosis (TB). My laboratory is investigating the hypothesis that persistence is enabled by entrance into and maintenance of a physiological state that is metabolically distinct from that of actively replicating bacilli. The aim of this work is to define this state (or series of states) and characterize pathways that are essential for its establishment and maintenance. My laboratory uses a variety of classical and novel approaches in mycobacterial genetics, biochemistry, physiology, and metabolomics to characterize i) novel aspects of intermediary metabolism in Mtb, ii) metabolic requirements for phenotypic drug tolerance, and iii) drug targets and drug-like compounds effective against persistent bacilli. While these studies address basic science questions about unique aspects of Mtb, they will also provide important contributions to the collaborative and global effort to eradicate TB.

Keywords

  • drug discovery
  • microbial genetics
  • metabolomics
  • tuberculosis
  • microbiology
  • drug mechanism
  • metabolism
  • drug resistance
  • tb

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 4 Similar Profiles
Mycobacterium tuberculosis Medicine & Life Sciences
Pyrazinamide Medicine & Life Sciences
Aminosalicylic Acid Medicine & Life Sciences
Bacteroides fragilis Medicine & Life Sciences
Tuberculosis Medicine & Life Sciences
Growth Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Folic Acid Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2011 2021

Pyrazinamide
Mycobacterium tuberculosis
Drug Tolerance
chelation
metals
Cyclic Peptides
Tuberculosis
Pharmaceutical Preparations
Mycobacterium tuberculosis

Research Output 2002 2019

Genomewide Assessment of Mycobacterium tuberculosis Conditionally Essential Metabolic Pathways

Minato, Y., Gohl, D. M., Thiede, J. M., Chacón, J. M., Harcombe, W. R., Maruyama, F., Baughn, A. D. & Dorrestein, P. C., Jun 25 2019, In : mSystems.

Research output: Contribution to journalArticle

4 Citations (Scopus)
Open Access
Aminosalicylic Acid
Mycobacterium tuberculosis
Folic Acid
Methionine
4-Aminobenzoic Acid
3 Citations (Scopus)

Mutual potentiation drives synergy between trimethoprim and sulfamethoxazole

Minato, Y., Dawadi, S., Kordus, S. L., Sivanandam, A., Aldrich, C. C. & Baughn, A. D., Mar 8 2018, In : Nature Communications. 9, 1

Research output: Contribution to journalArticle

14 Citations (Scopus)

Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA

Dillon, N. A., Peterson, N. D., Feaga, H. A., Keiler, K. C. & Baughn, A., Dec 1 2017, In : Scientific reports. 7, 1, 6135.

Research output: Contribution to journalArticle

Open Access
Pyrazinamide
Mycobacterium tuberculosis
Ribosomes
Oligonucleotides
RNA